Skip to content

Study · Not a test of the peptide alone · 2001

1 result

Oxindole derivatives as orally active potent growth hormone secretagogues.

Tokunaga T, Hume WE, Umezome T, Okazaki K, Ueki Y, Kumagai K, Hourai S, Nagamine J, Seki H, Taiji M, Noguchi H, Nagata R

Journal of medicinal chemistry1 Dec 2001Cited by 106 (Europe PMC)

PMID11741481 (opens in a new tab)DOI10.1021/jm0103763 (opens in a new tab)PepBankPUB-11741481
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking MK-677 (ibutamoren).

  1. 01LabNot a test of MK-677 (ibutamoren) aloneIn vitro (cell-free)Activity measurement

    In receptor binding assays, compound 37S displaced radiolabeled MK‑677 from human GHS-R with an IC50 of 1.2 +/- 0.2 nM.

    In plain wordsIn lab tests, compound 37S displaced labeled MK‑677 from the human receptor.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    DecreaseRadioligand displacement
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Pharmacology

    Measurements

    IC50
    1.2 nM
    compound 37S displacement

    Source sentences

    Summary
    Compound 37S displaced the binding of (35)S-MK-677 to human GHS-R with an IC(50) value of 1.2 +/- 0.2 nM.

    In this study, MK-677 (ibutamoren) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking MK-677 (ibutamoren).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.